Photocure Investor Hub

Investment highlights

A commercial-stage company focused on bladder cancer

Hexvix®/Cysview® is a product for the detection of bladder cancer:

  • Established position as an innovation leader in the large and underserved bladder cancer treatment market
  • Treatment guidelines and reimbursement supports market penetration
  • In excess of NOK 500 million in global revenue in 2023
  • Specialist salesforce established in the U.S. and Europe with additional potential value in other territories through our partners; Asieris MediTech Co., Ltd. (China), Endotherapeutics Group (Australia/New Zealand), Genotests (Chile) and IGL Medical (Israel)

Value-building opportunity

  • Large untapped potential for Hexvix®/Cysview® in existing and new market segments/territories
  • Potential for FDA to down-classify blue light cystoscopy and open the 510k pathway to enable more manufacturers to enter the U.S. market
  • Opportunity for Photocure to launch a proprietary flexible blue light cystoscope system to expand the surveillance market globally
  • Exploring expansion of bladder cancer portfolio to leverage commercial infrastructure

Investor news

Latest reports

Event highlights


American Urological Association's 2024 Annual Meeting (AUA)

3 May 2024 - 6 May 2024


Handelsbanken Nordic Small & Mid Cap Seminar

4 Jun 2024 - 5 Jun 2024

Analyst coverage Photocure ASA is followed by the analysts listed below. Please note that any opinions, estimates or forecasts regarding Photocure ASA's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Photocure ASA or its management. Photocure ASA does not by its reference below or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

ABG Sundal Collier


DNB Markets

Patrik Ling
Tel: +46 733 26 37 69


Rickard Anderkrans
Tel: +46 8 701 1995

Norne Securities AS

Tomas Skeivys
Tel: +47 21 95 37 49